Zimura, a complement factor C5 inhibitor, was found to be well tolerated in combination with Lucentis in a phase 2a clinical trial, Ophthotech announced in a press release.
Sixty-four patients with wet age-related macular degeneration were enrolled in the randomized, dose-ranging, open-label, multicenter phase 2a safety trial of Zimura (avacincaptad pegol) in combination with Lucentis (ranibizumab, Genentech). The treatment-naive patients were assigned to receive one of four dosing regimens.
“This uncontrolled clinical trial with a small sample size was not designed to detect a
Uncategorized